Immuneering Corporation
immuneering.comWhat Do They Do?
Develops oral cancer drug candidates aimed at people with solid tumors, including pancreatic cancer.
10-K for FY2025, filed Mar 6, 2026
Who Are Their Customers?
Previously provided computational biology services to pharmaceutical and biotechnology companies and partnered with companies in those industries for translational bioinformatics analyses.
10-K for FY2025, filed Mar 6, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$17.3MView ↗
- ▲ +20% (Loss)
- vs −$14.4M in Q2 FY2025
-
Jun 15, 2026
Named Andrew Gengos as incoming chief financial officer
He is expected to succeed Mallory Morales as principal financial officer; Morales will remain chief accounting officer.
Sources
8-K, filed Jun 15, 2026
On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as the Chief…View ↗
From services to internal drug development
The company previously provided computational biology services to pharmaceutical and biotechnology companies while developing its own drug pipeline; it has since ceased the services business and focused exclusively on its internal research and development programs.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 6, 2026
Loading...
